The US Food and Drug Administration has extended its review of AbbVie and Neurocrine’s experimental uterine pain drug elagolix by three months. More: US delay for AbbVie/Neurocrine’s uterine pain drug Source: News
read moreThe National Institute for Health and Care Excellence has now published final guidelines endorsing Merck and Pfizer’s Bavencio as an option for patients with Merkel cell carcinoma (MCC). More: Final guidance from NICE on Merck, Pfizer’s Bavencio Source: News
read moreRoche may have hit a snag in its bid to push a Tecentriq-Cotellic combo into colorectal cancer. The company temporarily stopped enrolling patients in a clinical trial after reports that four patients treated with the duo had died. More: Roche
read morePfizer has been looking to expand kidney cancer drug Inlyta’s use to renal cell carcinoma patients at a high risk of disease recurrence following surgery—but on that front, it’s fallen short. More: Pfizer strikes out on Inlyta expansion bid with postsurgery kidney cancer failure Source:
read moreA month after doling out its first grant ever—to help Themis develop vaccines against Lassa fever and MERS—the Coalition for Epidemic Preparedness Innovations has promised to fund Inovio’s efforts in the same diseases. More: On the heels of Themis deal,
read moreJust three days after celebrating another FDA approval for its ovarian cancer drug Rubraca, Clovis Oncology disclosed trouble with the feds. The SEC is zeroing in on Clovis’ once-promising therapy rociletinib, which went down in flames in 2015—and whether the
read more© 1994 - 2026 B.M. Pharmaceuticals